James Kirkland

James Kirkland is the pioneer of senolytic therapy, having conducted the first human clinical trials of dasatinib plus quercetin to eliminate senescent cells and reduce age-related disease burden including cancer risk. His hit-and-run dosing strategy for senolytics has demonstrated sustained benefits with intermittent treatment, minimizing toxicity while achieving lasting senescent cell clearance. He leads multiple phase I/II trials evaluating senolytics for cancer prevention in high-risk aging populations.